Pulmagen Therapeutics (Asthma) Limited

Pulmagen Therapeutics Limited

Neville McLean

John Gary Montana

George Hynd

Harry Finch

Rosa Arienzo

Michael Colin Cramp

Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: Ris halogen or cyano; Ris hydrogen or methyl; Rand Rare independently &#x2014;OR, C-Calkyl or C-Ccycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms; Ris hydrogen or halogen; Ris CCalkyl or C-Ccycloalkyl, either of which being optionally substituted by one or more halogen atoms; X is &#x2014;CH&#x2014;, &#x2014;S&#x2014;, or &#x2014;O&#x2014;; one of Y and Yis hydrogen and the other is OR, &#x2014;C(&#x2550;O)R, NRSORor a heterocyclic group selected from those referred to in the specification; and R, Rand Rare as defined in the specification.

Quinolines and their therapeutic use

Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: Ris halogen or cyano; Ris hydrogen or methyl; Rand Rare independently &#x2014;OR, C-Calkyl or C-Ccycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms; Ris hydrogen or halogen; Ris C-Calkyl or C-Ccycloalkyl, either of which being optionally substituted by one or more halogen atoms; X is &#x2014;CH&#x2014;, &#x2014;S&#x2014;, or &#x2014;O&#x2014;; one of Y and Yis hydrogen and the other is OR, &#x2014;C(&#x2550;O)R, NRSORor a heterocyclic group selected from those referred to in the specification; and R, Rand Rare as defined in the specification. 

Growing community of inventors

Essex, United Kingdom

Neville McLean